The evolution of NIPT: what comes next

In this talk, we will highlight how early, highly accurate prenatal screening optimizes outcomes for patients with 22q11.2 deletion syndrome, and review recently-published data from a large clinical v

Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk

Natera™'s Fetal RhD NIPT (noninvasive prenatal testing) is now available. The test is backed by the largest clinical validation study for fetal RhD in the US to date, and demonstrated 100 percent sens

Maternal health matters: findings from prenatal genetic screening with implications beyond pregnancy care

New Comprehensive Carrier Screening with Horizon Webinar

Overview of new Horizon panels and Natera's tools to streamline carrier screening workflow

New Comprehensive Carrier Screening with Horizon Webinar - Condensed

Overview of new Horizon panels and Natera's tools to streamline carrier screening workflow

It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

To manage pregnancies at high risk for 22q11.2 deletion syndrome (DS), prenatal and neonatal evaluation after high risk cfDNA screening is needed. Supplemental assessments and early intervention can i

Carrier Manifestations in Pregnancy

Utility of carrier screening to inform management